Psychotropic Medication Adherence

A special issue of Pharmacy (ISSN 2226-4787).

Deadline for manuscript submissions: closed (10 May 2020) | Viewed by 8737

Special Issue Editor


E-Mail Website
Guest Editor
Department of Pharmacy Practice and Sciences, School of Pharmacy, University of Maryland, Baltimore, MD 20742, USA
Interests: precision medicine; utilization of long-acting injectable psychotropics; psychotropic medication adherence; role of the psychiatric pharmacist on the treatment team
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Pharmacy—an open-access pharmacy education and practice journal—is preparing a Special Issue entitled “Psychotropic Medication Adherence”. Medication adherence is a major concern when treating patients with behavioral health disorders, one in which every team member must be involved. This issue will feature research and reviews regarding the current knowledge base regarding psychotopic medication adherence and potential solutions. I invite you to consider submitting an article related to psychotropic medication adherence to further the discussion regarding innovative solutions and techniques to assist patients.

Prof. Dr. Megan J. Ehret
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmacy is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • psychotropics
  • medication adherence
  • medication compliance
  • long-acting injectables
  • psychiatry

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Jump to: Review

14 pages, 307 KiB  
Article
Psychotropic and Opioid-Based Medication Use among Economically Disadvantaged African-American Older Adults
by Mohsen Bazargan, Sharon Cobb, Cheryl Wisseh and Shervin Assari
Pharmacy 2020, 8(2), 74; https://doi.org/10.3390/pharmacy8020074 - 27 Apr 2020
Cited by 3 | Viewed by 3177
Abstract
African-American older adults, particularly those who live in economically deprived areas, are less likely to receive pain and psychotropic medications, compared to Whites. This study explored the link between social, behavioral, and health correlates of pain and psychotropic medication use in a sample [...] Read more.
African-American older adults, particularly those who live in economically deprived areas, are less likely to receive pain and psychotropic medications, compared to Whites. This study explored the link between social, behavioral, and health correlates of pain and psychotropic medication use in a sample of economically disadvantaged African-American older adults. This community-based study recruited 740 African-American older adults who were 55+ yeas-old in economically disadvantaged areas of South Los Angeles. Opioid-based and psychotropic medications were the outcome variables. Gender, age, living arrangement, socioeconomic status (educational attainment and financial strain), continuity of medical care, health management organization membership, sleeping disorder/insomnia, arthritis, back pain, pain severity, self-rated health, depressive symptoms, and major chronic conditions were the explanatory variables. Logistic regression was used for data analyses. Arthritis, back pain, severe pain, and poor self-rated health were associated with opioid-based medications. Pain severity and depressive symptoms were correlated with psychotropic medication. Among African-American older adults, arthritis, back pain, poor self-rated health, and severe pain increase the chance of opioid-based and psychotropic medication. Future research should test factors that can reduce inappropriate and appropriate use and prescription of opioid-based and psychotropic medication among economically disadvantaged African-American older adults. Full article
(This article belongs to the Special Issue Psychotropic Medication Adherence)

Review

Jump to: Research

11 pages, 220 KiB  
Review
Ingestible Sensors and Medication Adherence: Focus on Use in Serious Mental Illness
by Azita Alipour, Stephen Gabrielson and Puja Baldev Patel
Pharmacy 2020, 8(2), 103; https://doi.org/10.3390/pharmacy8020103 - 16 Jun 2020
Cited by 17 | Viewed by 4982
Abstract
Background: Poor medication adherence is a major public health concern. Patients living with a serious mental illness (SMI) commonly present with non-adherence to their medication regimen, which can lead to relapse and hospitalizations. The high rates of antipsychotic non-adherence continue to persist despite [...] Read more.
Background: Poor medication adherence is a major public health concern. Patients living with a serious mental illness (SMI) commonly present with non-adherence to their medication regimen, which can lead to relapse and hospitalizations. The high rates of antipsychotic non-adherence continue to persist despite several interventions and medication advances. This review evaluates the possible role of the ingestible sensor technology for medication adherence in different conditions, with a focus on use in the SMI schizophrenia. Methods: Literature searches were conducted in July 2019 in the PubMed database. Results: In small studies of ingestible sensor use, the average adherence ranged from 73.9% to 88.6% for SMI and ≥ 80% for cardiac and transplant (99.4%) patients. In SMI studies, patients were clinically stable, and the majority had a clinical global impression severity of “mild disease”. Patients generally experienced relatively minor dermatological adverse effects related to wearable sensor use. Conclusions: A medication with an ingestible sensor may help provide real-time objective medication-taking adherence information for clinicians. However, further studies are needed to understand the impact of use on adherence and improvement on treatment outcomes with the ingestible sensor technology. Full article
(This article belongs to the Special Issue Psychotropic Medication Adherence)
Back to TopTop